[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pulmonary-tb\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pulmonary-tb":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100602068","phase-3-evaluating-a-shorter-rifampicin-based-treatment-for-people-with-less-severe-tuberculosis-disease-100602068",false,"NCT07118696","Evaluating a Shorter, Rifampicin-Based Treatment for People With Less Severe Tuberculosis Disease","Shortening TB Treatment With Optimised Rifampicin-Based Therapy and Disease Stratification: A Pragmatic Phase 3 Double-Blind Placebo-Controlled Randomised Trial (RIFAstrat)","RIFAstrat","Inclusion Criteria:\n\n1. Aged 12 years and over\n2. Clinical and\u002For radiological evidence of pulmonary TB\n3. At least one sputum specimen positive for M. tuberculosis by Xpert MTB\u002FRIF or Ultra within 30 days of screening confirming rifampicin-sensitive TB\n4. Have limited TB disease defined as having a cycle threshold on sputum Xpert MTB\u002FRIF or Ultra corresponding to 'medium' or below for bacterial burden at screening (where results from more than one test are available at screening, eligibility will be determined by the highest grade)\n5. Documentation of HIV status from a validated test performed within 30 days of screening or known to be HIV-positive\n6. Well enough to be treated as an outpatient\n\nExclusion Criteria:\n\n1. Received more than 7 days treatment for index TB episode\n2. Previous treatment for active TB disease in past 12 months\n3. M. tuberculosis with known resistance to rifampicin or isoniazid\n4. Weight \\\u003C 30 kg at screening\n5. Sick with one or more WHO 'danger signs' at screening (respiratory rate \\> 30 breaths per minute, temperature \\> 39 ˚C, heart rate \\> 120 bpm, inability to walk unaided)\n6. Suspected or confirmed extra-pulmonary TB involving the central nervous system, bones, joints, abdomen, and\u002For pericardium (coexistent pleural or lymph node TB are not exclusions)\n7. For participants living with HIV:\n\n   * Urinary lipoarabinomannan test positive at screening\n   * Requires protease inhibitor-based antiretroviral therapy, and\u002For long acting antiretrovirals cabotegravir\u002Frilpivirine\n8. For participants of child-bearing potential: currently pregnant or not currently pregnant but unwilling to practice an effective method of contraception during study drug treatment\n9. Clinical evidence of acute hepatitis or advanced chronic liver disease (e.g. jaundice, signs of portal hypertension)\n10. Known end stage renal failure\n11. Active malignancy not in remission or had systemic chemotherapy within 2 years (except for non-melanomatous skin cancer)\n12. Contraindication to study medications because of known allergy or intolerance or unavoidable drug-drug interaction\n13. Other medical conditions, that, in the investigator's judgment, make study participation not in the individual's best interest\n14. Inability to attend follow up visits","ALL","12 Years",{"count":20,"type":21},1000,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","RIFAstrat is a Phase 3, double-blind, placebo-controlled, non-inferiority trial to compare the 6-month standard treatment for DS-TB with a 4-month optimised- rifampicin based regimen provided to individuals with limited disease severity.",[27],"Pulmonary TB",[29,30],"Rifampicin","Treatment Shortening","NOT_YET_RECRUITING","2025-08-07",{"date":34,"type":35},"2025-08-12","ACTUAL",{"date":37,"type":21},"2026-02-01",{"date":39,"type":21},"2030-01-31",{"name":41,"class":42},"Hamilton Health Sciences Corporation","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":5},"100472041","risk-factors-and-biomarkers-for-post-tuberculosis-lung-damage-100472041","NCT05426720","Risk Factors and Biomarkers for Post-tuberculosis Lung Damage","Risk Factors and Biomarkers for Post-tuberculosis Lung Damage in a Chinese Cohort: Protocol for a Prospective Observational Study","Inclusion Criteria:\n\nMale patients aged 25-60 years newly diagnosed with active pulmonary TB.\n\nExclusion Criteria:\n\n1. patients with positive sputum smear or TB culture results;\n2. human immunodeficiency virus-positive patients;\n3. patients infected with multidrug-resistant TB;\n4. patients with malignant neoplasms (e.g., lung cancer) or severe cardiovascular and cerebrovascular diseases;\n5. non-compliant patients who were unable to complete the lung function tests;\n6. patients without lung parenchymal destruction (such as tuberculous pleurisy). -","MALE","25 Years","60 Years",{"count":54,"type":21},400,"OBSERVATIONAL","This prospective study aims to determine the incidence of Post-tuberculosis lung damage (PTLD), examine trends in the changes in lung function, and investigate the impact of smoking and other factors on respiratory symptoms, lung function, and chest CT findings, which will aid in the development of prognostic and therapeutic strategies for PTLD.",[27],[59,60],"post-tuberculosis lung damage","cigarette smoking","RECRUITING","2022-06-16",{"date":64,"type":35},"2022-06-22",{"date":66,"type":35},"2022-01-01",{"date":68,"type":21},"2027-12-31",{"name":70,"class":42},"Peking University Third Hospital"]